AM Pharma

AM-Pharma is a biopharmaceutical company developing recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to treat patients with Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.

Previously, the company developed and tested a bovine form of AP in three phase II trials in patients with sepsis, AKI and UC.AM-Pharma has since developed and manufactured a proprietary and fully human recombinant form of AP, known as recAP.

Timeline

September 13, 2011

AM Pharma raises a $39,843,400 series D round from Shire, IDInvest Partners, Ysios Capital, BB Biotech Ventures, Inventages Venture Capital Investment Inc., Kurma Life Science Partners, Abbott Laboratories and Forbion Capital Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
AM-Pharma funding round, July 2019
133,000,000
July 2019
Andera Partners
AM Pharma Series D round
Series D round
39,843,400
September 13, 2011
Abbott Laboratories
Shire (pharmaceutical company)
Forbion Capital Partners
IDInvest Partners
Ysios Capital
BB Biotech Ventures
Inventages Venture Capital Investment Inc.
Kurma Life Science Partners
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.